Commentaries

There is a better way — moving beyond the patents vs access debate: A Guest commentary

The debate about whether to suspend patent rights for COVID vaccines doesn’t need to be an “us vs. them” battle that pits access against innovation. Drawing on our previous work for Gilead, we propose a...

Pandemic response ushers in new era of biopharma data sharing: Guest Commentary

Years before the novel coronavirus began cutting its lethal course across nearly every continent on earth, scientists and senior executives at leading biopharmaceutical companies were discussing ways of accelerating the design, efficiency and pace of...

First-time CEOs must stop doing what made them successful: Guest Commentary

First-time CEOs of biotechs must not fall in the trap of continuing to excel in the domain areas their career success has been built on. Effectively stepping up to the chief executive role requires getting...

FDA should revamp its COVID-19 vaccine advisory committee meetings: Editor’s Commentary

One of the lessons from the COVID-19 experience is that influencing beliefs and actions is crucial for prevailing over a pandemic. Public health policies and medical countermeasures can only be implemented effectively if millions of...

What we must do to prepare for the next pandemic, a guest commentary

The U.S. is not ready for the next pandemic. Our public health infrastructure and planning process are not up to the challenge, our capacity to treat at-risk citizens is insufficient, and we are not making...

The U.S. needs a COVID commission: Editor’s Commentary

No country was better prepared for a pandemic than the United States and in no country has the response been as disastrously incompetent. The American public needs to know why. By the end of January,...

Truth and facts matter. Say it out loud: Editor’s Commentary

First they came for the climate scientists, and I did not speak out because I wasn’t a climate scientist. Then they came for the mask-wearers, and I did not speak out because I was...

Innovations forged in the COVID crucible will reshape medicine: Editor’s Commentary

The fight against COVID-19 is far from finished, but victory is close enough to start considering how the tools created to tame SARS-CoV2 will reshape the post-war world. As with World War II and the...

Guest Commentary: Speak out against burdensome restrictions on abortion medication or get ready for limits on other technologies

Unneeded, unscientific restrictions around access to abortion medication remain in place, perpetuating a two decade-long intrusion of politics where it does not belong.  The incoming Biden-Harris...

Two incentives that could open the floodgates to drug repositioning for COVID-19: Guest Commentary

With excitement of the encouraging data on COVID-19 prophylactic vaccines, let’s not forget the infection rate and mortality are higher than ever, and treatment options are limited. One of the missed opportunities...

The vaccine is here. Three questions about what happens next

The COVID-19 vaccine rollout is starting in the U.K., and is on the doorstep in the U.S. and Europe, building to a collective huge sigh of relief. The efficacy, at least for the first two,...

Biden time. 75 days to shape the coming 750 days: Editor’s Commentary

There is no time to celebrate or mourn the elections. The United States and the world are on the edge of a precipice and must act quickly to avoid disaster. It is reasonable to assume that...

中国版的Hatch-Waxman法案:同志仍需努力

Publisher's note: the English language version of this article may be found here. 今年10月17日,中国发布了第四次专利法修正案,其中引入了专利链接和专利期限延长两项制度,用以加强对药物发明的专利保护。可惜这些业界期盼已久的改革并不能为面对仿制药挑战的创新药企提供太多喘息的机会。 当这个新法在2021年6月生效时...

China’s Hatch-Waxman Act: Not there yet: Guest Commentary

On Oct. 17, China amended its patent law and introduced patent linkage and patent term extension to strengthen protection of pharmaceutical inventions. Unfortunately, the long-awaited changes are unlikely...

Protecting biomedical innovation as a national security asset: Guest Commentary

In recent years, it has become fashionable to focus on the high price of new treatments for certain cancers and rare diseases. Many observers ask why it is that U.S. citizens should subsidize the rest...